medicine
Contributions
Type: Publication Only
Background
Fatigue is the most invalidating symptom in neoplastic disease. Fatigue frequently is linked to an iron deficiency. In inflammatory diseases as myelodysplastic syndromes fatigue might be linked to a functional iron deficiency with elevated ferritin level and a saturation of total iron binding capacity < 20%.
Aims
Aim of this study is to verify if liposomial iron support in myelodysplastic syndromes as refractory anemia improves fatigue perception in patients with a saturation of total iron binding capacity < 20%.
Methods
Between june 2011and december2014,20patients affected by refractory anemia were studied.
Median follow-up was12 months(R10-24).Patients were randomized1:1 to receive in groupA alpha erythropoietin 40000IUsc/week+calcium levofolinate7.5mg/day orally+Vitamin B12:400mg/day orally.In group B patient received liposomial iron14mg1 tablet orally/day+alpha erythropoietin 40000IUsc/week+calcium levofolinate7.5mg/day orally+Vitamin B12:400 mg/day orally.In group A median age was60 years(R65-70),M/F:8/2.In groupB median age was66 years(R60-75),M/F:6/4.Caryotype was normal in groupA andB patients.Median level of haemoglobin was 9 g/dl in group A(R8.5-11) and8.8g/dl(R8.5-11.5)in group B.Fatigue was measured with Modified Fatigue Impact Scale (FISC - Fisk 1994).
Results
Patients in group A reached a median hemoglobin level of11.5g/dl after 3 month of therapy and referred a median FISC score of74 (R65-80). Patients in group B reached a median hemoglobin level of12.5g/dl after 3 month of therapy and referred a median FISC score of54 (R42-68).
Summary
Liposomial iron support improves fatigue perception in patients with refractory anemia. This study needs confirmation on a lager cohort of patients.
Keyword(s): Erythropoietin, Fatigue, Iron, Myelodysplasia
Type: Publication Only
Background
Fatigue is the most invalidating symptom in neoplastic disease. Fatigue frequently is linked to an iron deficiency. In inflammatory diseases as myelodysplastic syndromes fatigue might be linked to a functional iron deficiency with elevated ferritin level and a saturation of total iron binding capacity < 20%.
Aims
Aim of this study is to verify if liposomial iron support in myelodysplastic syndromes as refractory anemia improves fatigue perception in patients with a saturation of total iron binding capacity < 20%.
Methods
Between june 2011and december2014,20patients affected by refractory anemia were studied.
Median follow-up was12 months(R10-24).Patients were randomized1:1 to receive in groupA alpha erythropoietin 40000IUsc/week+calcium levofolinate7.5mg/day orally+Vitamin B12:400mg/day orally.In group B patient received liposomial iron14mg1 tablet orally/day+alpha erythropoietin 40000IUsc/week+calcium levofolinate7.5mg/day orally+Vitamin B12:400 mg/day orally.In group A median age was60 years(R65-70),M/F:8/2.In groupB median age was66 years(R60-75),M/F:6/4.Caryotype was normal in groupA andB patients.Median level of haemoglobin was 9 g/dl in group A(R8.5-11) and8.8g/dl(R8.5-11.5)in group B.Fatigue was measured with Modified Fatigue Impact Scale (FISC - Fisk 1994).
Results
Patients in group A reached a median hemoglobin level of11.5g/dl after 3 month of therapy and referred a median FISC score of74 (R65-80). Patients in group B reached a median hemoglobin level of12.5g/dl after 3 month of therapy and referred a median FISC score of54 (R42-68).
Summary
Liposomial iron support improves fatigue perception in patients with refractory anemia. This study needs confirmation on a lager cohort of patients.
Keyword(s): Erythropoietin, Fatigue, Iron, Myelodysplasia